type here...

CATEGORIES

Medication

LATEST

1234Page 2 of 4

TRENDING

EDITORS CHOICE

Exponential Innovation: Disrupting The Disruptor

John Nosta -
Today's world of disruptive change is defined by two terms: innovation and speed.  The big idea is important, but equally so is the path that innovation...

Achieve Life Sciences Announces Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers

Medika Life -
Clinical results in primary and secondary endpoints for 6- and 12-week experimental smoking cessation treatment reported by company sponsor.

First Drug Synthesized by AI Goes into Clinical Trials

Dr Sohail Merchant -
If all goes well, thanks to artificial intelligence, we may soon have a new AI-synthesized drug capable of assisting OCD patients in managing their symptoms and thus leading normal lives.

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

Medika Life -
SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories